Maximum dosage of norvasc
Pro Research Analysisby 
Searched over 200M research papers
Maximum Dosage of Norvasc (Amlodipine)
Introduction to Norvasc (Amlodipine)
Norvasc, known generically as amlodipine, is a calcium channel blocker used primarily to treat high blood pressure and angina. It works by relaxing blood vessels, allowing blood to flow more easily, and reducing the workload on the heart.
Recommended Dosage and Administration
The typical starting dose of Norvasc for adults is 5 mg once daily. Depending on the patient's response and the severity of the condition, the dosage can be increased. The maximum recommended dosage of Norvasc is 10 mg per day1.
Clinical Studies and Dosage Efficacy
In clinical trials, Norvasc has been evaluated for safety and efficacy at doses up to 10 mg daily. These studies have shown that treatment with Norvasc is generally well-tolerated, with most adverse reactions being mild to moderate in severity1. In a comparative study involving patients with chronic renal insufficiency and hypertension, Norvasc was administered at doses of 5 mg and titrated up to 10 mg daily. The study concluded that Norvasc effectively reduced blood pressure without significant adverse effects, confirming the safety of the 10 mg daily dosage2.
Safety and Side Effects
While Norvasc is generally safe, it is important to monitor for potential side effects, especially at higher doses. Common side effects include headache, edema, dizziness, flushing, and palpitations. These side effects tend to be dose-related, with higher incidences observed at the 10 mg dosage1.
Special Considerations
- Patients with Hepatic Impairment: Norvasc is extensively metabolized by the liver, and its plasma elimination half-life is prolonged in patients with impaired hepatic function. Therefore, caution is advised when administering Norvasc to these patients1.
- Heart Failure: Although Norvasc has been studied in patients with heart failure, it should be used with caution in this population. Clinical trials have shown no overall adverse effect on survival or cardiac morbidity in heart failure patients treated with Norvasc1.
Conclusion
The maximum recommended dosage of Norvasc is 10 mg per day. Clinical studies support the efficacy and safety of this dosage in treating hypertension and angina, although monitoring for dose-related side effects is essential. Special caution should be exercised in patients with hepatic impairment and heart failure.
Sources and full results
Most relevant research papers on this topic
It's time medicine stopped burying its mistakes.
NORVASC is a safe and effective oral calcium channel blocker for patients with heart failure, but caution is advised when using it with other medications.
Comparative study of Yashida and Norvasc in chronic renal insufficiency with hypertension
Yashida 5mg or 10mg daily is as effective and safe as Novasc in treating hypertension in chronic renal insufficiency patients.
RCT-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.
Amlodipine is an efficient and well-tolerated antihypertensive drug for patients with mild and moderate essential hypertension, with mild and transient side effects.
Non-RCTThe clinical efficacy of the calcium antagonist amlodipine in patients with ischemic heart disease and arterial hypertension
Amlodipine effectively reduces angina and ischemic symptoms in patients with ischemic heart disease and arterial hypertension, providing 24-hour antihypertensive activity without affecting well-being.
RCTEffect of Norvasc and Tanatril on circadian rhythm of blood pressure in hypertensive patients
Taking Norvasc and Tanatril together in the morning effectively controls blood pressure in dipper hypertensive patients, while nondipper hypertensive patients benefit more from taking the drugs separately in the morning and evening.
Non-RCTStability of amlodipine besylate in two liquid dosage forms.
Amlodipine besylate is stable in two liquid dosage forms for 91 days at 4 degrees C or 56 days at 25 degrees C, making it suitable for pediatric or elderly patients unable to swallow tablets and for accurate dose administration based on body weight.
Norfloxacin disposition after sequentially increasing oral doses
Single doses of norfloxacin (200, 400, 800, 1,200, and 1,600 mg) or placebo were administered orally at weekly intervals to 14 healthy male volunteers in a double-blind study. Norfloxacin was measured in serum and urine by high-pressure liquid chromatography with UV detection. The concentrations of this drug in serum peaked 1 to 2 h after each dose; the mean peak values for increasing doses were 0.75, 1.58, 2.41, 3.15, and 3.87 micrograms/ml. Mean area under the serum concentration-time curves for the first 12 h after each dose were 3.56, 6.26, 11.4, 16.1, and 19.7 micrograms . h/ml, respectively. The elimination half-life of norfloxacin was about 7 h and was similar for all doses. The concentrations of the drug in urine also peaked 1 to 2 h after dosage; mean peak values for increasing doses were 200, 478, 697, 992, and 1,045 micrograms/ml. Renal clearances approximated 285 ml/min. About 30% of each dose was excreted into urine as unmetabolized norfloxacin. Crystals of the drug were occasionally observed during microscopic examination of freshly voided urine collected after the 1,200- and 1,600-mg doses. Crystalluria was not encountered at lower doses.
RCT
Highly CitedDetermination of the 50% human infectious dose for Norwalk virus.
The 50% human infectious dose for Norwalk virus is higher than previously estimated and similar to that of other RNA viruses.
RCT
Rigorous JournalHighly CitedOverview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
Amlodipine reduces carotid intima-media thickness progression and significantly reduces unstable angina hospital admissions, but does not affect minor coronary lesions.
The Effect of Norvasc on Ambulatory Blood Pressure and Compliction of the Patients with Hypertension
Norvasc effectively controls blood pressure and reduces cardiovascular and cerebrovascular complications in patients with hypertension.
Observational Study